| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHINTE.160.10.1449 |
| P8608 | Fatcat ID | release_bo5h6pvpkrcjffqnuqk452lspi |
| P698 | PubMed publication ID | 10826457 |
| P2093 | author name string | Preston RA | |
| Materson BJ | |||
| Williams DW | |||
| Reda DJ | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | veteran | Q193891 |
| P304 | page(s) | 1449-1454 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | JAMA Internal Medicine | Q177428 |
| P1476 | title | Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study | |
| P478 | volume | 160 |
| Q34495779 | Antidepressants versus placebo in major depression: an overview |
| Q57072316 | Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses |
| Q42774701 | Antihypertensive treatment and compliance. Non-adherence should be addressed first |
| Q35681170 | Blood pressure control and factors predicting control in a treatment-compliant male veteran population |
| Q36214876 | Can we justify goal blood pressure of <140/90 mm Hg in most hypertensives? |
| Q26774165 | Dietary Nitrate Lowers Blood Pressure: Epidemiological, Pre-clinical Experimental and Clinical Trial Evidence |
| Q37610143 | Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis |
| Q35988524 | Differential Post-Exercise Blood Pressure Responses between Blacks and Caucasians |
| Q53444896 | Does the rising placebo response impact antihypertensive clinical trial outcomes? An analysis of data from the Food and Drug Administration 1990-2016. |
| Q35615485 | Effect of Placebo Conditions on Polysomnographic Parameters in Primary Insomnia: A Meta-Analysis |
| Q36177268 | Effect of placebo on ambulatory blood pressure monitoring in children |
| Q49926538 | Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension |
| Q30570112 | Finding unrecognized information in overactive bladder clinical trial data: A new approach to understanding placebo and treatment effects |
| Q41103874 | High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information-seeking about medication |
| Q47562184 | How to prove that your therapy is effective, even when it is not: a guideline |
| Q83705450 | Lessons to be learned from placebo groups in clinical trials |
| Q38206289 | Medicine's inconvenient truth: the placebo and nocebo effect |
| Q43784348 | Nebivolol Monotherapy for Patients With Systolic Stage II Hypertension: Results of a Randomized, Placebo-Controlled Trial |
| Q46822234 | Nocebo effects in multiple sclerosis trials: a meta-analysis |
| Q37942656 | Nocebo in fibromyalgia: meta‐analysis of placebo‐controlled clinical trials and implications for practice |
| Q34158126 | Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches |
| Q45981348 | Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. |
| Q34743314 | Physicians' preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs |
| Q38454219 | Placebo Effect and Efficacy of Nebivolol in Patients with Hypertension not Controlled with Lisinopril or Losartan: A Phase IV, Randomized, Placebo-Controlled Trial |
| Q42597050 | Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries |
| Q34199986 | Recent clinical trial highlights in hypertension |
| Q36713381 | Renal denervation: ultima ratio or standard in treatment-resistant hypertension |
| Q42574435 | Safety of placebo controls in pediatric hypertension trials |
| Q47434739 | Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia |
| Q73447821 | The diagnosis of Lyme disease: good news, bad news |
| Q38085499 | The placebo response in medicine: minimize, maximize or personalize? |
| Q33955541 | Treatment expectations and preferences as predictors of outcome of acupuncture for chronic back pain |
| Q35062333 | Uncontrolled hypertension as a risk for coronary artery disease: patient characteristics and the role of physician intervention |
| Q37699723 | Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials |
| Q30491637 | Withdrawal of antihypertensive medication: a systematic review |
Search more.